Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2020 | Sitravatinib with nivolumab in advanced clear cell RCC

Pavlos Msaouel • 13 Feb 2020
GU Cancers 2020
Genitourinary Cancer Kidney Cancer Nivolumab Sitravatinib

Pavlos Msaouel, MD, PhD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses the trial (NCT03015740) of sitravatinib combined with nivolumab in patients with advanced clear cell renal cell carcinoma (RCC). This interview took place at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.

More from Pavlos Msaouel

Drug repurposing and trial challenges in rare renal medullary carcinoma
3:11
Drug repurposing and trial challenges in rare renal medullary carcinoma
Pavlos Msaouel • 30 May 2026
Panitumumab-based EGFR blockade in SMARCB1-deficient RMC
2:40
Panitumumab-based EGFR blockade in SMARCB1-deficient RMC
Pavlos Msaouel • 30 May 2026
EGFR targeting and resistance in SMARCB1-deficient renal medullary carcinoma
1:49
EGFR targeting and resistance in SMARCB1-deficient renal medullary carcinoma
Pavlos Msaouel • 30 May 2026
Immune checkpoint therapy hyper-progression in renal medullary carcinoma
2:20
Immune checkpoint therapy hyper-progression in renal medullary carcinoma
Pavlos Msaouel • 26 Feb 2026

Related Videos

Current and emerging systemic strategies in biochemically relapsed prostate cancer
2:45
Current and emerging systemic strategies in biochemically relapsed prostate cancer
Ashwin Sachdeva • 16 May 2026
How has SABR improved radiotherapy practice in kidney cancer?
1:06
How has SABR improved radiotherapy practice in kidney cancer?
Shankar Siva • 16 May 2026
Which patients with kidney cancer may benefit from SABR treatment?
1:58
Which patients with kidney cancer may benefit from SABR treatment?
Shankar Siva • 16 May 2026
Management of brain metastasis in patients with poor-risk testicular cancer
1:03
Management of brain metastasis in patients with poor-risk testicular cancer
Darren Feldman • 30 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals